Information in respect of the offering of shares of DSM-Firmenich AG

Disclaimer

The information contained on this webpage gives access is exclusively intended for persons who are not residents of the United States or Australia, Canada, Japan, the Republic of South Africa and who are not physically present in the United States or Australia, Canada, Japan, the Republic of South Africa or any other jurisdiction where the extension of availability of the materials to which you are seeking access would breach any applicable law or regulation.  This information does not constitute an offer, or an invitation to purchase, securities of DSM-Firmenich AG (the "Company") in the United States, Australia, Canada, Japan, the Republic of South Africa or in any other jurisdiction in which such offer or invitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation.  Potential users of this information are requested to inform themselves about and to observe any such restrictions.

The Company’s securities cannot be offered or sold in the United States without registration under the United States Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from such registration, or offered or sold into Australia, Canada, Japan, or the Republic of  South Africa under any applicable securities laws of any state, province, territory, county or jurisdiction of Australia, Canada, Japan, or the Republic of  South Africa.  The Company has not registered, and does not intend to register, any of its securities under the Securities Act or under any applicable securities laws or to conduct a public offering of securities in the United States, Australia, Canada, Japan, or the Republic of South Africa. Any securities offered by the Company are being offered and sold solely outside the United States in reliance on Regulation S under the Securities Act.

The information to which this gatepost gives access is only directed at persons in member states of the European Economic Area (the "EEA"), other than the United Kingdom, who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129), as amended ("Qualified Investors").  In addition, in the United Kingdom, the materials are being distributed only to, and are directed only at, Qualified Investors who are (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (b) high net worth entities falling within Article 49(2)(a) to (d) of the Order; and (c) other persons to whom it may otherwise lawfully be communicated (all such persons referred to in (a), (b) and (c) together being referred to as "Relevant Persons").  Any investment or investment activity to which the materials relate is available only to Relevant Persons in the United Kingdom and Qualified Investors in any member state of the EEA, other than the United Kingdom, and will only be engaged with such persons.

By proceeding to view the materials to which the links on this webpage give access, you warrant that you are not located in the United States, Australia, Canada, Japan, or the Republic of South Africa or any other jurisdiction where accessing these materials is unlawful and you agree that you will not transmit or otherwise send any information contained in this website to any person in the United States, Australia, Canada, Japan, or the Republic of South Africa or any other jurisdiction where accessing these materials is unlawful or to publications with a general circulation in the United States, Australia, Canada, Japan, or the Republic of South Africa or any other jurisdiction where to do so would breach applicable local law or regulation.

Press releases

DSM-Firmenich AG launches the sale of up to c. 6.7 million existing DSM-Firmenich ordinary shares through an accelerated bookbuild offering

24.05.2023

DSM-Firmenich AG announces the successful placement of c. 6.7 million existing DSM-Firmenich ordinary shares through an accelerated bookbuild offering for a total amount of €733 million 

25.05.2023

Explore more